Welcome to our dedicated page for Ventas SEC filings (Ticker: VTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ventas, Inc. filings document the regulatory record of a healthcare real estate investment trust whose common stock trades on the New York Stock Exchange under VTR. The company’s disclosures include Form 8-K reports for operating results, quarterly and annual earnings releases, dividend-related events, material financing agreements and capital markets activity.
Recent filings also cover amendments to credit facilities, registered senior notes issued by Ventas Realty, Limited Partnership and guaranteed by Ventas, ATM sales agreement updates, officer-transition disclosures and proxy materials addressing director elections, executive compensation, shareholder voting matters and governance.
Ventas, Inc. filed a Form 4 reporting an insider share acquisition. Director Joe V. Rodriguez, Jr. acquired 46.173 common stock units on 10/16/2025 as dividend equivalents under the Non-Employee Directors' Equity Award Deferral Program adopted pursuant to the 2022 Incentive Plan. These units are payable solely in common stock. The closing price per share as of the grant date was $69.55. After the transaction, he beneficially owned 7,764.461 shares, held directly.
Ventas, Inc. (VTR) reported an insider transaction by a director. On October 16, 2025, the reporting person acquired 74.76 units of common stock credited as dividend equivalents under the Ventas Non-Employee Directors' Equity Award Deferral Program adopted pursuant to the 2022 Incentive Plan. The units are payable solely in common stock, using the $69.55 closing price per share as of the grant date. After this transaction, the reporting person beneficially owned 21,290.153 shares, held directly.
Ventas (VTR): Director Roxanne M. Martino reported an acquisition of 201.433 shares of common stock on 10/16/2025, credited as dividend-equivalent units under the Ventas Non-Employee Directors' Cash Compensation Deferral Plan. The grant is payable solely in common stock and reflects the dividend paid on October 16, 2025. The price reference was the $69.55 closing price on the grant date. After this transaction, her beneficial ownership is 62,417.095 shares, held directly.
Ventas (VTR) director Matthew J. Lustig reported routine acquisitions of common stock units on October 16, 2025 from dividend equivalents credited under director deferral programs. He received 250.738 units under the Non-Employee Directors' Cash Compensation Deferral Plan and 74.76 units under the Non-Employee Directors' Equity Award Deferral Program, each valued at the closing price of $69.55 per share as of the grant date. After these credits, he directly beneficially owned 91,546.943 shares.
Ventas, Inc. (VTR): Director Michael J. Embler acquired 74.76 units payable in common stock on October 16, 2025 as dividend equivalents under the Non‑Employee Directors' Equity Award Deferral Program adopted pursuant to the 2022 Incentive Plan. The transaction was coded “A” (acquisition) in Table I. The filing notes a reference price of $69.55 per share as of the grant date. After this credit, Embler beneficially owned 14,520.153 shares, held directly.
Ventas, Inc. (VTR) director Melody C. Barnes reported an acquisition of 74.76 shares of common stock on 10/16/2025. The shares reflect units credited as dividend equivalents under the Non-Employee Directors' Equity Award Deferral Program and are payable in common stock, consistent with her deferral election.
The filing cites a closing price of $69.55 per share on the grant date. After this transaction, Barnes directly owned 33,125.153 shares.
Debra A. Cafaro, Chairman and CEO of Ventas, Inc. (VTR), reported transactions dated 10/01/2025 on Form 4 showing the exercise and sale of 10,322 shares. She exercised fully vested stock options with an exercise price of $65.45 that were exercisable from 05/04/2016 and scheduled to expire 05/04/2026. The shares were sold under a Rule 10b5-1 trading plan entered 03/28/2024 at a weighted average sale price of $70.237. After the transactions, her reported beneficial ownership was 1,145,695 shares and she holds 670,965 unexercised options.
Peter J. Bulgarelli, an executive at Ventas, Inc. (VTR), reported two open-market sales executed under a Rule 10b5-1 trading plan entered on February 20, 2025. On 09/30/2025 he sold 2,040 shares at $69.99, reducing his stake to 119,042 shares. On 10/01/2025 he sold 2,554 shares at a weighted-average price of $70.2566, leaving him with 116,488 shares. The filing states the 10b5-1 plan covers these sales and discloses the reported price range of $69.9931 to $70.4706, with the reporting person offering to provide detailed per-trade quantities on request.
This Form 144 notice reports a proposed sale of 2,554 shares of Ventas, Inc. common stock through Northern Trust Securities with an aggregate market value of $179,435.36 and an approximate sale date of 10/01/2025. The filer acquired these shares as compensation shares on 01/25/2022 from Ventas, Inc.
The filing also discloses recent sales by the same person: 406 shares sold on 09/15/2025 for $28,418.94 and 2,040 shares sold on 09/30/2025 for $142,779.60. Outstanding shares reported on the form are 454,471,192, indicating the proposed sale is de minimis relative to total shares outstanding. The filer affirms no undisclosed material adverse information.
Ventas, Inc. (VTR) Form 144: This notice reports a proposed sale of 2,040 shares of Ventas common stock through Northern Trust Securities, Inc. on 09/30/2025 with an aggregate market value of $142,779.60. The shares were acquired as compensation shares on 01/25/2022 from Ventas, Inc. The filing also discloses that 406 shares were sold on 09/15/2025 by Peter J. Bulgarelli for $28,418.94. The filing includes the standard representation that the selling person does not possess undisclosed material adverse information and references Rule 10b5-1 plan adoption language, but no plan adoption date or signature block details are provided in the content supplied.